CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges
Briefings in Functional Genomics · 20.05.2020 · 19 (3) · 209-214
DOI: 10.1093/bfgp/elaa001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Briefings in Functional Genomics, online erschienen am 12.02.2020. Verfasst von Xing Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany.
- Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine,Guangzhou, China.
- Department of Rehabilitation, Huai'an Second People's Hospital, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
- Department of Orthopaedics, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zitieren
APA
Cheng, X., Fan, S., Wen, C., & Du, X. (2020). CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges. Briefings in Functional Genomics, 19(3), 209-214. https://doi.org/10.1093/bfgp/elaa001
Vancouver
Cheng X, Fan S, Wen C, Du X. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges. Briefings in Functional Genomics. 2020;19(3):209-214. doi:10.1093/bfgp/elaa001
BibTeX
@article{Cheng2020,
author = {Cheng, Xing and Fan, Shaoyi and Wen, Chengcai and Du, Xianfa},
title = {CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges},
journal = {Briefings in Functional Genomics},
year = {2020},
volume = {19},
number = {3},
pages = {209--214},
doi = {10.1093/bfgp/elaa001}
}
EUVIMED